Enanta Pharmaceuticals, Inc.ENTANASDAQ
Loading
Other Income/Expenses (Net) Over TimeContracting
Percentile Rank20
3Y CAGR-63.5%
5Y CAGR-31.4%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
-63.5%/yr
vs -8.4%/yr prior
5Y CAGR
-31.4%/yr
Recent deceleration
Acceleration
-55.1pp
Decelerating
Percentile
P20
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$302000.00-83.2%
2025$1.80M-53.9%
2024$3.90M-37.2%
2023$6.21M+275.1%
2022$1.66M-17.0%
2021$1.99M-69.9%
2020$6.62M-24.9%
2019$8.82M+84.0%
2018$4.79M+105.4%
2017$2.33M-